PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
123.99%
Positive ROE while AVXL is negative. John Neff would see if this signals a clear edge over the competitor.
-254.57%
Negative ROA while AVXL stands at 237.69%. John Neff would check for structural inefficiencies or mispriced assets.
30.73%
ROCE above 1.5x AVXL's 18.49%. David Dodd would check if sustainable process or technology advantages are in play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.